AR046272A1 - Inhibidores de dipeptidil peptidasa iv - Google Patents

Inhibidores de dipeptidil peptidasa iv

Info

Publication number
AR046272A1
AR046272A1 ARP040103608A ARP040103608A AR046272A1 AR 046272 A1 AR046272 A1 AR 046272A1 AR P040103608 A ARP040103608 A AR P040103608A AR P040103608 A ARP040103608 A AR P040103608A AR 046272 A1 AR046272 A1 AR 046272A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
ring
cycloalkyl
het1
Prior art date
Application number
ARP040103608A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR046272A1 publication Critical patent/AR046272A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los compuestos de la presente son valiosos en el tratamiento de los estados patológicos asociados con la actividad de la DPP-IV, como por ejemplo la diabetes mellitus. También se describen procesos para la preparación de los mencionados compuestos, los intermediarios utilizados en dichos procesos, composiciones farmacéuticas que contienen dichos compuestos o sales y el uso de dichos compuestos o sales. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la cual Ar es fenilo optativamente sustituido con 1, 2, 3, 4 o 5 grupos independientemente seleccionados entre R9; R9 se selecciona entre halo, alquilo C1-6 (optativamente sustituido con halo 1-5), alcoxi C1-6 (optativamente sustituido con 1-5 halo) y ciano; R1 se selecciona entre H y alquilo C1-6, R2 se selecciona entre H, alquilo C1-6, cicloalquilo C3-8, bicicloalquilo C5-12, tricicloalquilo C6-12, AR1, HET1, -alquil C1-6AR1, -alquil C1-6AR2, -alquil C1-6-cicloalquilo C3-8, -alquil C1-6HET1, -alquil C1-6HET2, -alquil C1-6CO2alquilo C1-6, -alquil C1-6CO2cicloalquilo C3-8, -alquil C1-6CO2AR1, -alquil C1-6CO2HET1, -alquil C1-6OCOalquilo C1-6, -alquil C1-6OCOcicloalquilo C3-8, -alquil C1-6OCOAR1, -alquil C1-6OCOHET1, -alquil C1- 6COalquilo C1-6, -alquil C1-6COcicloalquilo C3-8, -alquil C1-6COAR1, -alquil C1-6COHET1, -alquil(C1-6)NHCOalquilo C1-6, -alquil C1-6NHCOcicloalquilo C3-8, -alquil C1-6NHCOAR1, -alquil C1-6CONHalquilo C1-6, -alquil C1-6CONHcicloalquilo C3-8, -alquil C1-6CON-dialquilo C1-6, -alquil C1-6CONHAR1, -alquil C1-6NHalquilo C1-6, -alquil C1-6N-dialquilo C1-6, -alquil C1-6NHAR1, -alquil C1-6NH(HET1), -alquil C1-6NHSO2alquilo C1-6, -alquil C1-6SO2NHalquilo C1-6, -alquil C1-6SO2alquilo C1-6, -SO2alquilo C1- 6 y -alquil C1-6SO2N-dialquilo C1-6; o R1 y R2, junto con el N al cual están unidos, forman un anillo definido por HET1 o HET3; donde un anillo que comprende R1 y R2 está optativamente sustituido con 1 o 2 sustituyentes independientemente seleccionados entre halo, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, ciano, carboxi, carboxialquilo C1-6, -COalquilo C1-6, -CO2alquilo C1-6, alquilamino C1-6, di-alquilamino C1-6-amino, -NHCOalquilo C1-6, -CONHalquilo C1-6, -CONdi-alquilo C1-6 y HET1; R3 y R4 se seleccionan independientemente entre H, alquilo C1-6, cicloalquilo C3-8, cicloalquenilo C3-8, bicicloalquilo C5-12, -alquil C1-6-cicloalquilo C3-8, -alquil C1-6-cicloalquenilo C3-8, AR1, AR2, HET1, HET2, -alquil C1-6AR1, -alquil C1- 6AR2, -alquil C1-6HET1 y -alquil C1-6HET2; o R3 y R4 juntos forman un anillo definido por cicloalquilo C3-8, AR2, HET1 o HET2, R5, R6, R7 y R8 se seleccionan independientemente entre H y alquilo C1-6, donde cualquier grupo alquilo C1-6 comprendido en cualquier definición de R1, R2, R3, R4, R5, R6, R7 o R8 está optativamente sustituido con 1 ó 2 sustituyentes independientemente seleccionados entre hidroxi y F; donde cualquier cicloalquilo C3-8, cicloalquenilo C3-8, bicicloalquilo C5-12 o tricicloalquilo C6-12 incluido en cualquier definición de R2, R3 o R4 está optativamente sustituido; AR1 es fenilo optativamente sustituido; AR2 es un anillo carbocíclico bicíclico de 8, 9 o 10 miembros insaturado, parcial o completamente saturado, optativamente sustituido; HET1 es un anillo heterocíclico monocíclico insaturado, parcial o completamente saturado de 3, 4 o 6 miembros, optativamente sustituido que contiene hasta 4 heteroátomos independientemente seleccionados entre O, N y S (aunque sin contenido alguno de enlaces O-O, O-S o S-S), ligado por medio de un átomo de C, o un átomo de N del anillo si el anillo no fuera así cuaternizado y donde cualquier átomo de C, S o N libre pueda oxidarse; HET2 es un anillo de heterociclilo bicíclico insaturado, parcial o completamente saturado de 8, 9 o 10 miembros, optativamente sustituido, que contiene hasta cuatro heteroátomos independientemente seleccionados entre O, N y S (aunque sin contenido de enlaces O-O, O-S o S-S), ligado por medio de un átomo de C del anillo en cualquiera de los anillos que comprende el sistema bicíclico; HET3 es un sistema de anillos saturados bicíclicos o tricíclicos ligado con N, que contiene hasta 12 átomos en el anillo, incluyendo el átomo de N ligante; donde los sustituyentes optativos adecuados en cicloalquilo C3-8, bicicloalquilo C5-12, tricicloalquilo C6-12, AR1, AR2, HET1 y HET2 son 1, 2, 3, 4 o 5 sustituyentes independientemente seleccionados entre fenilo (optativamente sustituido con halo, trifluorometilo, alquilo C1-4 o alcoxi C1-4), halo, alquilo C1-6, haloalquilo C1-6, dihaloalquilo C1-6, trifluormetilo, alcoxi C1-6, carboxialquilo C1-6, carboxialcoxi C1-6, hidroxi, amino, alquil C1-6-amino, dialquil C1-6- amino, -CONH2, -CONHalquilo C1-6, -CONdialquilo C1-6, -NHCOalquilo C1-6, -SO2alquilo C1-6, -S(O)2NH2, -SO2NHalquilo C1-6, -SO2Ndialquilo C1-6 y -NHSO2alquilo C1-6.
ARP040103608A 2003-10-16 2004-10-05 Inhibidores de dipeptidil peptidasa iv AR046272A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0324236.9A GB0324236D0 (en) 2003-10-16 2003-10-16 Chemical compounds

Publications (1)

Publication Number Publication Date
AR046272A1 true AR046272A1 (es) 2005-11-30

Family

ID=29559397

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103608A AR046272A1 (es) 2003-10-16 2004-10-05 Inhibidores de dipeptidil peptidasa iv

Country Status (5)

Country Link
AR (1) AR046272A1 (es)
GB (1) GB0324236D0 (es)
TW (1) TW200523234A (es)
UY (1) UY28564A1 (es)
WO (1) WO2005040095A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP1875921A1 (en) * 2005-04-27 2008-01-09 Ajinomoto Co., Inc. Dpp4 inhibitor and pharmaceutical application thereof
WO2007063928A1 (ja) * 2005-11-30 2007-06-07 Toray Industries, Inc. 新規な非環状アミンカルボキシアミド誘導体及びその塩
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2007734A1 (en) 2006-04-12 2008-12-31 Probiodrug AG Enzyme inhibitors
EP1905759A1 (en) * 2006-09-07 2008-04-02 Santhera Pharmaceuticals (Schweiz) AG N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment oftype 2 diabetes mellitus
WO2008028662A1 (en) * 2006-09-07 2008-03-13 Santhera Pharmaceuticals (Schweiz) Ag N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
CN101279955B (zh) * 2007-04-03 2012-11-28 北京摩力克科技有限公司 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
CN102918027A (zh) 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012035549A2 (en) 2010-09-13 2012-03-22 Panacea Biotec Ltd An improved process for the synthesis of beta amino acid derivatives
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
MX2017016530A (es) 2015-06-22 2018-03-12 Arena Pharm Inc Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10025464A1 (de) * 2000-05-23 2001-12-06 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen
EP1406622B1 (en) * 2001-06-20 2006-02-22 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003031410A1 (en) * 2001-10-09 2003-04-17 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto

Also Published As

Publication number Publication date
WO2005040095A1 (en) 2005-05-06
TW200523234A (en) 2005-07-16
UY28564A1 (es) 2005-05-31
GB0324236D0 (en) 2003-11-19

Similar Documents

Publication Publication Date Title
AR046272A1 (es) Inhibidores de dipeptidil peptidasa iv
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR050274A1 (es) Derivados triciclicos del indeno-pirrol como moduladores de la serotonina
AR038419A1 (es) Derivados de piridina y quinolina
UY28374A1 (es) Agentes terapéuticos
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
UY28144A1 (es) Agentes terapéuticos
PE20061397A1 (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos productos y metodos de preparacion
AR053832A1 (es) Derivados de pirrolidina 3,4 sustituida para el tratamiento de la hipertension
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR060220A1 (es) Compuestos heterociclicos de 5 o 6 miembros, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades asociadas con la dgat1.
AR059016A4 (es) Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
AR061222A1 (es) Derivados de 2-oxo-piridina, 2-oxo-quinolina y 2-oxo-isoquinolina, composiciones farmaceuticas que los comprenden y el uso de los mismos en medicamentos para tratar enfermedades mediadas por la scd.
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
MA31766B1 (fr) Composés organiques
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AR053415A1 (es) Inhibidores dipeptidil peptidasa iv, composiciones farmaceuticas que los contienen y procesos para la preparacion de los compuestos y de la composicion
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure